Patrick Brown of Stanford University and Stephen Fodor, CEO of Affymetrix, have been jointly awarded the 2002 Takeda Award in the field of individual/humanity well-being (life sciences), the Takeda Foundation announced this week. They receive the prize for “the development and promotion of DNA microarrays.” The award, established by the Tokyo-based Takeda Foundation last year, comes with about ¥ 100 million ($833,000) in prize money. The award ceremony will take place on November 20 in Tokyo.
Steve Lombardi has become Affymetrix's vice president of corporate development, reporting to Robert Lipshutz, senior vice president of corporate development and licensing. Prior to his appointment, Lombardi was senior vice president of applications and products at Applied Biosystems. His other positions during 16 years at ABI included vice president of field operations for the Americas, vice president for genetic analysis, product manager for genetic analysis, and product manager for DNA sequencing and DNA synthesis. Lombardi holds a BA in biology from Merrimack College.
Norrie Russell has been appointed president and CEO of San Diego-based biochip maker Aviva Biosciences (see page 4). He joins the company from Lynx Therapeutics, where he was president and CEO until June of this year. At Aviva, Russell, who holds a PhD in physiology from Glasgow University, succeeds Peter Wilding, who will become chairman of Aviva’s board of directors. Charles Sie, the company’s founding chairman, will remain a member of the board.
Gary McMaster has been appointed CSO of Fremont, Calif.-based GenoSpectra. He joins the company from Eli Lilly and Company, where he was director of target discovery and systems biology research. Previously, he was senior director of molecular biology at Pfizer, and he spent ten years at Novartis and Ciba-Geigy. He also held research management positions at the Max Planck Institute for Immunology and at Hoffman-La Roche Pharmaceuticals. McMaster received a PhD in developmental biology from the Swiss Institute for Experimental Cancer Research.